(Incorporated in the Cayman Islands)

We are a pioneering provider of end-to-end innovative hemp dosing solutions in the U.S. We sell nebulizers. We engage in key activities in the hemp cannabinoid e-vapors industry, including research and development, formulation design, e-liquid production, e-liquid filling and e-liquid co-packing services. We believe our full-cycle operations and leading market position will position us to further capitalize on the growth potential of the U.S. hemp cannabinoid e-vapors market.

Our leading atomization technology, AiMesh® technology, significantly facilitates precise metering control, and our high-end aroma molecule blending technology, feelmixX® technology, perfectly combines traditional CBD oil with modern e-vapor oil, positioning us to provide broader applications across different sectors. Our hemp cannabinoid e-vapors are marketed under the Cannapresso brand name, primarily on an Original Design Manufacturer (“ODM”) basis to other hemp vapor companies. ODM generally involves the design and customization of the core products to meet a brand’s unique image and needs. Our products are sold by our customers under their own brand names although they may also include our brand name on the products.

Note: Net income and revenue are for the 12 months that ended Sept. 30, 2025.

(Note: Papa Medical, Inc. filed a new S-1 on Nov. 26, 2025, for its small IPO – 1.5 million shares at $4.00 to raise $6 million – with a new sole book-runner, Kingswood Capital Markets – to replace its previous IPO plans filed in 2024 (1.25 million shares at $4.00 to raise $5 million in a deal lead by U.S. Tiger Securities and TFI Securities.)